C. Murray, T. Vos, R. Lozano, M. Naghavi, A. D. Flaxman et al., Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010, Lancet, vol.380, issue.9859, pp.2197-223, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00827610

W. S. Gilmer, M. H. Trivedi, A. J. Rush, S. R. Wisniewski, J. Luther et al., Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project, Acta Psychiatr Scand, vol.112, issue.6, pp.425-458, 2005.

J. A. Murphy and G. J. Byrne, Prevalence and correlates of the proposed DSM-5 diagnosis of chronic depressive disorder, J Affect Disord, vol.139, issue.2, pp.172-80, 2012.

A. J. Rush, M. Zimmerman, S. R. Wisniewski, M. Fava, S. D. Hollon et al., Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features, J Affect Disord, vol.87, issue.1, pp.43-55, 2005.

A. J. Rush, M. H. Trivedi, S. R. Wisniewski, A. A. Nierenberg, J. W. Stewart et al., Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report, Am J Psychiatry, vol.163, issue.11, pp.1905-1922, 2006.

M. H. Trivedi, A. J. Rush, S. R. Wisniewski, A. A. Nierenberg, D. Warden et al., Evaluation of outcomes with citalopram for depression using measurementbased care in STAR*D: implications for clinical practice, Am J Psychiatry, vol.163, issue.1, pp.28-40, 2006.

L. Samalin, M. Abbar, P. Courtet, S. Guillaume, S. Lancrenon et al., Society for Biological Psychiatry and Neuropsychopharmacology task force: formal consensus for the prescription of depot antipsychotics, Encéphale, vol.39, issue.4, pp.189-203, 2013.

M. Bauer, A. Pfennig, E. Severus, P. C. Whybrow, J. Angst et al., World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders, World J Biol Psychiatry, vol.14, issue.5, pp.334-85, 2013.

. Gelenberg, Practice guideline for the treatment of patients with major depressive disorder. In: American psychiatric association, 2010.

S. H. Kennedy, R. W. Lam, R. S. Mcintyre, S. V. Tourjman, V. Bhat et al., Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the Management of Adults with major depressive disorder: section 3. Pharmacological treatments, Can J Psychiatr, vol.61, issue.9, pp.540-60, 2016.

A. Cleare, C. M. Pariante, A. H. Young, I. M. Anderson, D. Christmas et al., Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines, J Psychopharmacol (Oxford), vol.29, issue.5, pp.459-525, 2015.

, Depression: The Treatment and Management of Depression in Adults (Updated Edition), National Institute for Health and Clinical Excellence: Guidance, 2010.

M. H. Pollack, Comorbid anxiety and depression, J Clin Psychiatry, vol.66, issue.8, pp.22-31, 2005.

D. S. Baldwin, E. H. Reines, C. Guiton, and E. Weiller, Escitalopram therapy for major depression and anxiety disorders, Ann Pharmacother, vol.41, issue.10, pp.1583-92, 2007.

K. Rickels and E. Schweizer, The treatment of generalized anxiety disorder in patients with depressive symptomatology, J Clin Psychiatry, vol.54, pp.20-23, 1993.

H. Wittchen, Generalized anxiety disorder: prevalence, burden, and cost to society, Depress Anxiety, vol.16, issue.4, pp.162-71, 2002.

M. Mavissakalian, Antidepressants in the treatment of agoraphobia and obsessive-compulsive disorder, Compr Psychiatry, vol.24, issue.3, pp.278-84, 1983.

J. Fawcett and R. L. Barkin, A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety, J Clin Psychiatry, vol.59, issue.3, pp.123-130, 1998.

P. J. Goodnick, A. Puig, C. L. Devane, and B. V. Freund, Mirtazapine in major depression with comorbid generalized anxiety disorder, J Clin Psychiatry, vol.60, issue.7, pp.446-454, 1999.

M. Muehlbacher, M. K. Nickel, C. Nickel, C. Kettler, C. Lahmann et al., Mirtazapine treatment of social phobia in women: a randomized, doubleblind, placebo-controlled study, J Clin Psychopharmacol, vol.25, issue.6, pp.580-583, 2005.

J. Davidson, Treatment of posttraumatic stress disorder: the impact of paroxetine, Psychopharmacol Bull, vol.37, issue.1, pp.76-88, 2003.

M. A. Sugarman, I. Kirsch, and J. D. Huppert, Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: a meta-analysis, J Affect Disord, vol.218, pp.217-243, 2017.

S. Pallanti, L. Quercioli, R. S. Paiva, and L. M. Koran, Citalopram for treatment-resistant obsessive-compulsive disorder -Eur Psychiatry, vol.14, pp.101-107, 1999.

J. B. Diniz, R. G. Shavitt, V. Fossaluza, L. Koran, C. A. Pereira et al., A doubleblind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder, J Clin Psychopharmacol, vol.31, issue.6, pp.763-771, 2011.

D. E. Adson, M. G. Kushner, K. M. Eiben, and S. C. Schulz, Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors, Depress Anxiety, vol.19, issue.2, pp.121-127, 2004.

D. E. Adson, M. G. Kushner, and T. A. Fahnhorst, Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors, J Affect Disord, vol.86, issue.1, pp.99-104, 2005.

L. I. Yargic, A. Corapcioglu, N. Kocabasoglu, A. Erdogan, G. Koroglu et al., A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety, Int J Psychiatry Clin Pract, vol.8, issue.4, pp.205-216, 2004.

A. Mcintyre, A. Gendron, and A. Mcintyre, Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study, Depress Anxiety, vol.24, issue.7, pp.487-94, 2007.

J. D. Coplan, C. J. Aaronson, V. Panthangi, and Y. Kim, Treating comorbid anxiety and depression: psychosocial and pharmacological approaches, World J Psychiatry, vol.5, issue.4, pp.366-78, 2015.

E. Karyotaki, H. Riper, and P. Cuijpers, Internet-based self-help interventions for depression in routine care-reply, JAMA Psychiatry, vol.74, issue.8, p.853, 2017.

E. V. Nunes and F. R. Levin, Treatment of co-occurring depression and substance dependence: using meta-analysis to guide clinical recommendations, Psychiatr Ann, vol.38, issue.11, p.128505, 2008.

B. K. Tolliver and R. F. Anton, Assessment and treatment of mood disorders in the context of substance abuse, Dialogues Clin Neurosci, vol.17, issue.2, pp.181-90, 2015.

J. R. Cornelius, T. A. Chung, A. B. Douaihy, L. Kirisci, J. Glance et al., A review of the literature of mirtazapine in co-occurring depression and an alcohol use disorder, J Addict Behav Ther Rehabil, vol.5, issue.4, 2016.

G. Newton-howes, P. Tyrer, and T. Johnson, Personality disorder and the outcome of depression: meta-analysis of published studies, Br J Psychiatry, vol.188, pp.13-20, 2006.

B. H. Mulsant, D. M. Blumberger, Z. Ismail, K. Rabheru, and M. J. Rapoport, A systematic approach to pharmacotherapy for geriatric major depression, Clin Geriatr Med, vol.30, issue.3, pp.517-551, 2014.

A. F. Schatzberg, C. Kremer, H. E. Rodrigues, and G. M. Murphy, Mirtazapine vs. paroxetine study group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients, Am J Geriatr Psychiatry, vol.10, issue.5, pp.541-50, 2002.

K. Patel, S. Allen, M. N. Haque, I. Angelescu, D. Baumeister et al., Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant, Ther Adv Psychopharmacol, vol.6, issue.2, pp.99-144, 2016.

A. C. Fernandes, D. Chandran, M. Khondoker, M. Dewey, H. Shetty et al., Demographic and clinical factors associated with different antidepressant treatments: a retrospective cohort study design in a UK psychiatric healthcare setting, BMJ Open, vol.8, issue.9, p.22170, 2018.

T. N. Jilani, A. Saadabadi, and . Mirtazapine, Treasure Island (FL): StatPearls Publishing, StatPearls [Internet, 2018.